Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Professor Kumlesh Dev

Professor (Physiology)
BIOMEDICAL SCIENCES INSTITUTE

 devk@tcd.ie

 3531896 4180

Professor (Trinity Inst. of Neurosciences (TCIN))


Research Tags

  DEMYELINATION   Drug development   Glial biology   Neuroscience

Representations

Details Date
Consortium Member, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School, (EU-collaborative network providing training opportunities to PhD students in Trinity) 2020-Current
President, Frontiers in Neurology Ireland (FIN) (Held for 7 years, in recognition within area of Drug Development & Neurology) 2011-2017
Council Member, Society for Neuroscience Ireland (Held for 3 years, developing travel grant applications in the society) 2013-2015
Council Member, Swiss Tissue Culture Society (Held for 2 years, international society focused on cell-based drug discovery) 2005-2006
Member, Society for Neuroscience (Recognised as the major neuroscience society globally) 2000-Current
Editorial Board Member, Brain, Behavior, and Immunity (Impact Factor 7.217, Quartile Q1, 16/156 Psychiatry Journals) 2016-Current
Editorial Board Member, Scientific Reports (Impact Factor 4.379, Quartile Q1) 2014-2019
Editorial Board Member, Journal of Biological Chemistry (Impact Factor 5.157, Quartile Q1, In top 75% Biochem & Cell Journals) 2005-2011
Editor, Frontiers in Behavioral Neuroscience (Drug Development in Rare Demyelinating Diseases), (4th cited open access in Neurosci) 2022
Editor, Special Issue In Cancers (Cangliomics - Repositioning Drugs for Cancer Gliomas), (Impact Factor 6.639) 2021-Current
Editor, Special Issue In Neuropharmacology (Lipid Sensing G Protein-Coupled Receptors in the CNS), (Impact Factor 5.251) 2017
Editor, Special Issue In Current Drug Targets (Common Receptor Signalling in Glial and Immune Cells), (Impact Factor 3.030) 2016
External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland 2020-Current
Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy 2020-Current
External Examiner, PhD Thesis (External Examiner of multiple PhD Thesis, approx. 1-2 per year) 2009-Current
External Consultant, Pharma and Biotech Industries (Consultant Role in scientific review of multiple biotech and pharma companies) 2009-Current

Memberships

Membership of Professional Institutions, Associations, Societies

Details Date From Date To
Consortium Member, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School 2020 Current
Fellow, Trinity College Dublin (FTCD) 2014 Current
President, Frontiers in Neurology Ireland (FIN) 2011 2017
Council Member, Society for Neuroscience Ireland 2013 2015
Council Member, Swiss Tissue Culture Society 2005 2006
Member, Society for Neuroscience 2000 Current
Editorial Board Member, Brain, Behavior, and Immunity 2016 Current
Editorial Board Member, Scientific Reports 2014 2019
Editorial Board Member, Journal of Biological Chemistry 2005 2011
Fagan SG, Bechet S, Dev KK. , Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease , Mol Neurobiol, Online ahead print, 2022, Journal Article, PUBLISHED
Mekhaeil M, Dev KK, Conroy MJ. , Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases , Cancers, Online ahead print, 2022, Journal Article, PUBLISHED
Mampay M, Velasco-Estevez M, Rolle SO, Chaney AM, Boutin H, Dev KK, Moeendarbary E, Sheridan GK. , Spatiotemporal immunolocalisation of REST in the brain of healthy ageing and Alzheimer's disease rats., FEBS Open Bio, 11, 2021, p146 - 163, Journal Article, PUBLISHED
Velasco-Estevez M, Koch N, Klejbor I, Laurent S, Dev KK, Szutowicz A, Sailer AW, Rutkowska A. , EBI2 Is Temporarily Upregulated in MO3.13 Oligodendrocytes during Maturation and Regulates Remyelination in the Organotypic Cerebellar Slice Model. , Int J Mol Sci. , 22, 2021, p4342-, Journal Article, PUBLISHED
Clementino A, Velasco-Estevez M, Buttini F, Sonvico F, Dev KK. , Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo., Neurotherapeutics, Online ahead print, 2021, Journal Article, PUBLISHED
Velasco-Estevez, M. and Koch, N. and Klejbor, I. and Laurent, S. and Dev, K.K. and Szutowicz, A. and Sailer, A.W. and Rutkowska, A., Ebi2 is temporarily upregulated in mo3.13 oligodendrocytes during maturation and regulates remyelination in the organotypic cerebellar slice model, International Journal of Molecular Sciences, 22, (9), 2021, Notes: [cited By 2], Journal Article, PUBLISHED  DOI
Velasco-Estevez M, Rolle SO, Mampay M, Dev KK, Sheridan GK., Piezo1 regulates calcium oscillations and cytokine release from astrocytes., Glia, 68, 2020, p145 - 160, Journal Article, PUBLISHED  DOI
Velasco-Estevez M, Gadalla KKE, Liñan-Barba N, Cobb S, Dev KK, Sheridan GK., Inhibition of Piezo1 attenuates demyelination in the central nervous system., Glia, 68, 2020, p356 - 375, Journal Article, PUBLISHED  DOI
Béchet S, O'Sullivan SA, Yssel J, Fagan SG, Dev KK., Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease., Journal of Neuroscience, 40, 2020, p3104 - 3118, Journal Article, PUBLISHED  DOI
Neyman S, Braunewell K-H, O'Connell KE, Dev KK, Manahan-Vaughan D, Inhibition of the Interaction Between Group I Metabotropic Glutamate Receptors and PDZ-Domain Proteins Prevents Hippocampal Long-Term Depression, but Not Long-Term Potentiation, Frontiers in Synaptic Neuroscience, 11, 2019, p13 , Journal Article, PUBLISHED  TARA - Full Text  DOI
  

Page 1 of 12
Dev KK, 6th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 186, 2017, p281 - 298, Journal Article, PUBLISHED
Dev KK, 5th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 185, 2016, p169 - 185, Journal Article, PUBLISHED
Dev KK, 4th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 184, 2015, p1 - 18, Journal Article, PUBLISHED
Dev KK, Neurology, Professor Kumlesh Dev sets out Ireland's position on brain disease. Irish Independent (Supplement), 2015, -, Miscellaneous, PUBLISHED
Dev KK, 3rd Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci. , 183, 2014, p71 - 85, Journal Article, PUBLISHED
Dev KK, 2nd Annual Meeting. Block MS Ireland. Neuroprotection: At the cellular, in vivo and clinical level., Irish J Med. Sci., 182, 2013, p1 - 13, Journal Article, PUBLISHED

  

Awards and Honours

Award Date
External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland (Recognises leadership in research and teaching in Neuroscience) 2020-Current
Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy 2020-Current
Fellow, Trinity College Dublin (FTCD) 2014-Current
Wellcome Trust, Over €0.65 million, Multiple Awards latest award 2021
Enterprise Ireland, Over €0.14 million, Multiple Awards latest award 2021
Health Research Board, Over €1.09 million, Multiple Awards latest award 2018
Industry Over €0.96 million, Multiple Awards latest award 2018
Irish Research Council, Over €0.14 million Multiple Awards latest award 208
Science Foundation Ireland, Over €0.28 million, Multiple Awards latest award 2017
Charities, Over €0.60 million, Multiple Awards latest award 2007
Consortium Trinity Lead, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School latest award 2022
Work Package Lead and Course Director, HEA, Human Capital Initiative (Pillar 3) latest award 2021
Work Package Lead and Course Director, HEA, Human Capital Initiative (Pillar 1) latest award 2020
Project Collaborator, HEA, PRTLI, Ireland Award latest award 2014
Editor, Special Issue, Frontiers in Behavioral Neuroscience 2022
Editor, Special Issue, Cancers 2021
Editor, Special Issue, Neuropharmacology 2017
Editor, Special Issue, Current Drug Targets 2016

Research Interests

Description Of Research Interests

My research is focused in areas of Drug Development and Neuroscience. My research integrates fields of molecular biology, cell science, and drug discovery. It integrates the areas of cell biology, medicine and pharmaceuticals. I established the Drug Development group at Trinity, which investigates mechanisms underlying brain diseases, particularly demyelinating diseases such as Multiple Sclerosis, and also with a focus on rare paediatric illnesses including Krabbes disease (KD). KD causes fatality in infants and has no cure. My group has identified new compounds, repositioned marketed drugs, developed novel nanoparticle technology and created nasal delivery methods that demonstrate efficacy models of KD. These findings are published in top-tier neuroscience and neurotherapeutic journals and are of international recognition. This research is translational, where the developed technologies are on a potential path of clinical development, subject of patent application, commercialisation and the basis of EU grant applications, supported by Enterprise Ireland. My research has transformed our understanding of how marketed drugs used in Multiple Sclerosis work, and how they directly regulate brain cells. This work is pioneering, highly cited and uncovered novel cell mechanisms leading to development of new therapeutic strategies. This work demonstrates an ongoing transformational nature of my activities. My research is competitively recognised and well supported by national and international funding agencies as well as multinational pharmaceutical industry and biotech. I have been awarded over €5.7 million in funding, published almost 100 papers and have an H-index of over 40. I am a board member and reviewer of several international journals, advisor and consultant to large pharmaceutical and biotech companies and I have been President of Frontier of Neurology Ireland for 7 years, bringing to Ireland and Trinity links from across Europe and US, and bringing support from multiple large pharma and research funding agencies. My work has also been highlighted in national press in the area of neurology and drug development. I have significant expertise in drug development and a global network within multiple pharma and biotech industry. I have provided leadership to large research and drug discovery projects and successfully delivered follow-on compounds of marketed drugs, for Multiple Sclerosis. I have published extensively in my area of research of brain cell biology, specifically glial cells. The journal Glia is the highest journal in this field in which my research is being published on a yearly basis. A pubmed search in my focussed area indicates 10% of articles being from my group, many are highly cited. The approaches used by my group, integrating human brain cells and brain slice studies are also unique. The drug testing platform established in my group attracts multiple industry collaborations. I am regularly invited as a Consultant to guide and review drug development projects. I have provided Consultant assistance to drug development of nearly 100 various pharma and biotech companies. With these activities, I have a world leader recognition in my area of drug development. My mission is to teach within the emerging field of drug development as well as develop new medicines.